Novel autism marker and application thereof
By identifying the level of IFT172 haplod inadequate dose, systems and drugs for autism were developed for diagnosis and treatment, and the diagnosis problem of the correlation between IFT172 haplod inadequate dose and autism was solved, and effective diagnosis of autism was achieved. treat.
Patent Information
- Application Number
- CN202411035965.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-12-06
AI Technical Summary
The correlation between IFT172 haplogenic inadequate dose and autism and its diagnostic mechanism are still unclear, and it is difficult for the prior art to effectively diagnose and treat autism spectrum disorders.
Identification of IFT172 haplod inadequate levels through high-throughput sequencing, quantitative PCR, protein electrophoresis and other methods, providing systems and therapeutic drugs for autism diagnosis, including IFT172 overexpression reagents, BDNF overexpression reagents, BDNF mimic compounds and TrkB Antagonists such as 7,8-DHF are used to detect and treat autism.
It was found that mice with low IFT172 haplogenic dose showed self-censoring, increased anxiety and decreased cognitive ability. RNA sequencing and electron microscopy confirmed the differences in synaptic plasticity-related pathways. 7,8-DHF was used to restore BDNF-TrkB signaling activity and Behavioral phenotypes provide new diagnostic and targeted therapeutic avenues.
Smart Images

Figure CN119082283A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of disease diagnosis, and in particular to the application of IFT172 haploinsufficiency as an autism marker. Background Art
[0002] Cilia are a highly conserved cell structure that protrudes from the apical surface of most eukaryotic cells and can be divided into kinocilia and static cilia (primary cilia). Both kinocilia and static cilia are rooted in the cytoplasm through the basal body, a special structure that also serves as the mother centriole of the microtubule organizing center during mitosis. Primary cilia play a key role in maintaining the normal structure and function of cells and the stability of the internal environment. More and more evidence shows that primary cilia may be important signal "receptors" of cells.
[0003] Mutations in genes encoding ciliary proteins can lead to a range of inherited pleiotropic disorders, called ciliopathies, that often involve multiple organs and neurodevelopmental defects. Bardet-Biedl syndrome (BBS) is a common, mild ciliopathy that is typically characterized by retinitis pigmentosa, polydactyly, obesity, renal insufficiency, male hypogonadism, and mental retardation. Most genes involved in BBS encode essential proteins for basal body, transition zone, or intraflagellar transport (IFT). IFT is a bidirectional transport process required for protein transport between the cytoplasm and cilium, initiating ciliary assembly and maintenance. IFT172, also known as selective lipid domain binding protein (SLB), is the largest component of IFT protein complex B and works in concert with other IFT and kinesins to facilitate anterograde transport as well as cargo return at the ciliary tip. In humans, mutations in IFT172 lead to multiple ciliopathies, including BBS.
[0004] Alterations in brain neurotrophic support, especially abnormal expression and activity of brain-derived neurotrophic factor (BDNF), have long been implicated as contributing to a variety of neuropsychiatric disorders, including autism spectrum disorders. BDNF can regulate neuronal assembly, differentiation, and maturation in the peripheral and central nervous systems by binding to its cognate tyrosine kinase receptor, TrkB, thereby inducing synaptic plasticity and neuronal dendritic spine remodeling.
[0005] However, the association of IFT172 deficiency caused by mutations in IFT172 with autism and its mechanism remain unclear. Summary of the invention
[0006] To address the above deficiencies, the present invention studied the correlation between Ift172 haploinsufficiency (Ift172+ / -) and autistic symptoms such as self-grooming, increased anxiety and decreased cognitive ability, and explored its mechanism.
[0007] Specifically, the first aspect of the present invention provides the use of IFT172 haploinsufficiency as a marker for preparing autism diagnostic reagents.
[0008] In certain embodiments, the autism is autism spectrum disorder (ASD).
[0009] In certain embodiments, the level of IFT172 haploinsufficiency is identified by high-throughput sequencing, quantitative PCR, protein electrophoresis, and the like.
[0010] The second aspect of the present invention provides an autism research method for non-disease diagnosis and treatment purposes, the method comprising detecting the IFT172 haploinsufficiency level in a subject; using the IFT172 level value of a normal person as a control; an IFT172 haploinsufficiency level lower than the control indicates a high risk of autism.
[0011] The third aspect of the present invention provides a system for diagnosing autism, comprising: 1) a reagent for detecting the haploinsufficiency level of IFT172 in a subject; 2) a device, comprising a data input module, a data comparison module and a conclusion output module.
[0012] In certain embodiments, the data input module is used to input the haploinsufficiency level of IFT172 in the sample to be tested; the data comparison module is used to compare the haploinsufficiency level of IFT172 in the sample to be tested with a control value; the control value is the IFT172 level of a normal person; the conclusion output module is used to output the conclusion according to the following standards: if the haploinsufficiency level of IFT172 in the sample to be tested is lower than the control, it indicates a high risk of autism.
[0013] A fourth aspect of the present invention provides the use of an agent for eliminating or alleviating the defects caused by haploinsufficiency of IFT172 in the preparation of a drug for treating autism.
[0014] In certain embodiments, the agent is selected from an IFT172 overexpression agent, a BDNF overexpression agent, a BDNF mimetic compound, and / or a TrkB agonist.
[0015] In certain embodiments, the TrkB agonist is 7,8-DHF.
[0016] Compared with the prior art, the present invention has the following beneficial effects:
[0017] The present invention first discovered that Ift172 haploinsufficient (Ift172+ / -) mice exhibited excessive self-grooming, elevated anxiety, and impaired cognitive abilities. RNA sequencing results showed enrichment of differentially expressed genes in pathways associated with axonogenesis and synaptic plasticity, which was further confirmed by reduced dendritic spine density and synapse number as shown by sparse neuron labeling and electron microscopy. Ift172+ / - mice had reduced parvalbumin-expressing neurons, reduced inhibitory synaptic transmission, and enhanced theta oscillations and sharp wave ripples in the CA1 region. In addition, Ift172 haploinsufficiency led to reduced BDNF expression. Application of 7,8-dihydroxyflavone completely restored BDNF-TrkB signaling activity and abnormal behavioral phenotypes and cognitive abilities in Ift172+ / - mice. Luciferase and chip assays showed that Gli3 may physically interact with BDNF promoter I and regulate BDNF expression. Ift172 itself also drives neurotrophic effects, and if defective, it may cause neurodevelopmental disorders and cause autism-like disorders.
[0018] The present invention provides new insights into understanding the ASD-like phenotype prevalent in BBS patients and paves new avenues for targeted treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:
[0020] Figure 1Showing that Ift172+ / - mice exhibit abnormal behavioral phenotypes. (A) Strategy for generating Ift172+ / - mice using CRISPR / cas9-mediated genome editing technology; (B) Representative Western blot analysis showing reduced expression of Ift172 in the testis of Ift172+ / - mice (n=2, 3 replicates per group); (C) Relative expression levels of Ift172 mRNA in the testis of WT and Ift172+ / - mice (n=6 per group); (D) Ift172+ / - mice spent more time grooming compared to wild-type mice (n=5 per group); (EF) Ift172+ / - mice exhibited stronger edge-movement in the open field test (n=12 or 14 per group); (G) Representative heatmap of the open field test; (H) On the first day, Ift172+ / - mice and WT littermates showed no place preference in the three chambers (n=12 per group); (I, J) Compared with wild-type mice, Ift172+ / - mice showed no interest in unfamiliar mice on the second day (I) and no interest in unfamiliar mice on the third day (II); (K) Representative heat map of the three-chamber social test showed that Ift172+ / - mice had social impairment; (L) Ift172+ / - mice showed mild stereotypic behavior in the bead burying test (n=12 and 14 per group); (MN) Ift172+ / - mice showed spontaneous memory impairment in the novel object recognition (M) and conditioned fear test (N); Data are expressed as mean ± sem (Student's t test or one-way ANOVA with Tukey's multiple-comparisons test. *p<0.05, **p<0.01, and ***p<0.001).
[0021] Figure 2 RNA sequencing data of the hippocampus of WT and Ift172+ / - mice for transcriptome analysis are shown. (A) Volcano plot shows that there are 939 differentially expressed genes (DEGs) in the hippocampus of Ift172+ / - mice and WT littermates, of which 516 are upregulated and 423 are downregulated; (B) Heat map shows the relative changes in mRNA levels of 939 differentially expressed genes (red, upregulated; blue, downregulated). Each row represents a differentially expressed gene and each column represents an independent sample. (C) Gene ontology (GO) analysis showed that DEGs are mainly involved in axonogenesis and axon development. (D) Gene clustering heat map of ASD-related postsynaptic proteins. Data are normalized from two replicates (n=2).
[0022] Figure 3Figure 3: Ift172 haploinsufficiency results in dysfunctional BDNF-TrkB signaling and reduced synaptic density. (A) Ift172+ / - mice have reduced expression of BDNF, p-TrkB, p-Erk1 / 2, and PSD95 in the cortex compared with wild-type littermates. (B) Quantitative analysis of relative levels of protein expression (n = 3 per group). (C) Immunohistochemical staining shows reduced expression of BDNF in the brains of Ift172+ / - mice compared with wild-type mice. Scale bar = 2 mm (left column) and 10 μm (right column). (D) Immunofluorescence staining of IFT172 and BDNF in the cortex of WT and Ift172+ / - mice. Scale bar = 20 μm. (E) Quantitative analysis of IFT172 and BDNF protein expression (n = 5 per group). (F) Schematic diagram showing the construction of adeno-associated viruses and the sparse labeling strategy. (G) Representative confocal images of pyramidal neurons and their apical dendrites in the CA1 region of WT and Ift172+ / - mice. Scale bars = 10 μm (top row) and 5 μm (bottom row). (H) Dendritic spine density was significantly reduced in Ift172+ / - mice compared with wild-type mice. (WT: n = 11 dendrites from 3 mice; Ift172+ / -: n = 5 dendrites from 3 mice). (I) Representative electron microscopy images of synaptic structures in the CA1 region. Red arrows indicate synapses. Scale bars = 1 μm. (J) Quantitative analysis of synaptic density in WT and Ift172+ / - mice. (n = 5 per group). Data are shown as mean ± sem (*p < 0.05, **p < 0.01, and ***p < 0.001, Student's t-test)
[0023] Figure 4Showing that Ift172+ / - mice exhibit abnormal inhibitory synaptic transmission, theta oscillations, and sharp wave ripples (SWRs) in the CA1 region. (A, B) Ift172+ / - mice show fewer neurons expressing parvalbumin (PV) in the CA1 region (n=6 per group). (CE) Both the amplitude and frequency of sIPSCs were significantly reduced in Ift172+ / - mice. (F) Schematic diagram of in vivo electrophysiological recording and implantation of a 16-channel electrode array in the hippocampus. (G) Typical multi-channel recording results of LFP and SWRs. (H, I) Ift172+ / - mice show more SWRs with a higher incidence (H) and normal duration (I). (J) Ift172+ / - mice have similar SWR burst patterns to their WT littermates. (K) Relative power differences of Delta (1-3 Hz), Theta (3-7 Hz), Alpha (7-12 Hz), Beta (12-30 Hz), Gamma (30-100 Hz), and Episilon (100-250 Hz) in the CA1 region between Ift172+ / - mice and WT littermates. Scale bar in A = 50 μm. Data are presented as mean ± sem. *p < 0.05, **p < 0.01. SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum.
[0024] Figure 5 Figure 7 shows that the use of 7,8-DHF rescued the behavioral alterations of Ift172+ / - mice. (A, B) Compared with the control group, Ift172+ / - mice showed more activity in the open field test after 7,8-DHF treatment (n = 11 per group). (C) Representative heat map of the open field test. (D) On the first day of the three-box social test, Ift172+ / - mice showed no place preference after 7,8-DHF treatment. (E, F) Compared with the control group, Ift172+ / - mice treated with 7,8-DHF showed significantly improved social interaction preference on the second day (E) and third day (F) of the test. (G) Representative heat map showing the activity of mice in the three-box social test test. (H, I) In the novel object recognition (H) and fear conditioning test (I), the spontaneous memory of Ift172+ / - mice was also greatly improved after the use of 7,8-DHF. (J) Ift172+ / - mice did not show any improvement in the number of buried beads even after 7,8-DHF treatment. Data are presented as mean ± SEM (one-way ANOVA with Student's t-test or Tukey's multiple comparison test). *p<0.05, **p<0.01, ns indicates no significant difference.
[0025] Figure 6Gli3 binds to the BDNF promoter and regulates its transcription. (A) After transfection with Ift172-specific siRNA, the expression of Gli3 (including activated and repressed forms) and BDNF in SH-SY5Y cells was reduced. (B) After transfection with specific Ift172 siRNA, the expression level of BDNF mRNA in SH-SY5Y cells was significantly reduced (n=6 per group). (C, D) Both Western blot and RT-qPCR analysis showed that SH-SY5Y cells transfected with gli3-specific siRNA reduced the expression levels of BDNF protein and mRNA (n=3 per group). (E, F) Overexpression of Gli3 enhanced the expression levels of BDNF protein and mRNA in SH-SY5Y cells (n=6 per group). (G) Schematic diagram showing the coding region of BDNF and the potential binding sites of Gli3. (H) Luciferase assay showed that Gli3 recognized and bound to the BDNF exon I promoter. Mutation of this promoter completely abolished the luciferase activity (n=6 per group). (I) ChIP-PCR assay showed that Gli3 specifically binds to the promoter binding motif of BDNF exon I. The primers used in this PCR can bind to the BDNF exon I promoter binding site. PCR assay also included each input sample. Positive controls were anti-histone H3 antibody and GAPDH primers. Data are shown as mean ± sem (Student's t-test. **p < 0.01 and ***p < 0.001). Western blot data are representative of three independent experiments. DETAILED DESCRIPTION
[0026] In order to make the purpose, technical solution and advantages of the embodiment of the present invention clearer, the technical solution of the embodiment of the present invention will be clearly and completely described below in conjunction with the accompanying drawings of the embodiment of the present invention. Obviously, the described embodiment is a part of the embodiment of the present invention, not all of the embodiments. Based on the described embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0027] Unless otherwise defined, technical or scientific terms used herein shall have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs.
[0028] Example 1 Materials and Methods
[0029] 1.1 Antibodies
[0030] The following primary antibodies were used: anti-Ift172 (Invitrogen, #PA5-43702), anti-BDNF (Affinity, #DF6387), anti-Gli3 (Novusbio, #NBP2-29627), anti-Gli2 (1:500; Santa Cruz, #sc-271786), anti-PSD95 (Cell Signaling Technology, #3450), anti-p-TrkB (Abcam, #ab97072), anti-TrkB (Cell Signaling Technology, #4603), anti-p-Erk1 / 2 (Cell Signaling Technology, #4370), anti-Erk1 / 2 (Cell Signaling Technology, #4371), and anti-P-TrkB (Abcam, #ab97072). Technology, #4695), anti-GAPDH (Proteintech, #60004-1-Ig), anti-Satb2 (Abcam, #ab92446), anti-Ctip2 (Abcam, #ab18465), anti-Tle4 (Santa Cruz, #sc-365406), anti-Parvalbumin (Swant, PV27), anti-Arl13B (Proteintech, #17711-1-AP), anti-Foxp2 (Abcam, #ab16046); anti-Ctip2 (Abcam, #ab18465), anti-Cux1 (Oasisbiofarm, #OB-PRB038-01), anti-Calbindin (Sigma, #c2724), anti-Prox1 (Abcam, #ab199359) and anti-Ki67 (Abcam, #ab15580).
[0031] 1.2 Cell lines, mice, and treatment
[0032] HEK293 and SH-SY5Y cells were cultured in high-glucose DMEM or DMEM / F12, respectively. The culture medium was supplemented with 10% FBS and penicillin (100 units / ml) / streptomycin (100 μg / ml). Ift172+ / - mice were generated by GemPhamatech (Nanjing, China) on a C57BL / 6 background using the CRISPR / Cas9 strategy. sgRNA guided the Cas9 endonuclease to cleave introns 2 and 9 and generate single-strand breaks. Mice were housed in a specific pathogen-free (SPF) environment in accordance with the guidelines of the Second Xiangya Hospital of Central South University.
[0033] In the rescue experiment, 7,8-DHF was dissolved in saline containing 0.5% CMC-Na and 5% DMSO. Age-matched male Ift172+ / - mice were randomly assigned to control and experimental groups and then gavaged with saline (0.5% CMC-Na and 5% DMSO) or 7,8-DHF (10 mg / kg) daily for 8 weeks. They were then subjected to a series of behavioral tests.
[0034] 1.3 Cell transfection and infection
[0035] The information of plasmids and siRNA is as follows: HA / Flag-Gli3 (Addgene, #51245), Flag / ZsGreen-Gli2 and shRNA-Gli2 (Shanghai Gene Chemical Co., Ltd.), siRNA Gli3 (Santa Cruz Biotechnology, #sc-35483). Nano293T (New Saimei, #C500T-1) and Lipofectamine3000 (Invitrogen, #L3000075) were used for transfection of HEK293 and SH-SY5Y. For specific steps, please refer to the experimental protocol provided by the manufacturer. The transfection medium is opti-MEM (Invitrogen, #31985070). The transfected cells were harvested after culturing at 37°C for 48 hours for further experiments.
[0036] 1.4 Protein electrophoresis experiment
[0037] Prepare whole cell lysate, lyse cultured cells and mouse brain tissue in RIRA buffer (NCM, #WB3100) containing a mixture of protease and phosphatase inhibitors on ice for 15 minutes. The lysate was centrifuged at 14,000 rpm for 15 minutes at 4°C, and the supernatant was collected. The protein concentration was determined by the BCA method. Then, an equal amount of protein was loaded and protein electrophoresis was performed using the primary antibody in Example 1.1.
[0038] 1.5 Real-time PCR
[0039] Total RNA was extracted with Trizol (Magen, #R4801-01) according to the manufacturer's instructions. Reverse transcription was performed using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher, #K16225). Gene-specific primers were designed and purchased by Shanghai Shenggong Biotechnology Co., Ltd. All real-time PCR reactions were performed using the PowerUp SYBY Master Mix Kit (Thermo Fisher, #A25742). 480II 96 (Roche). Relative quantification of gene expression was calculated using the 2-ΔΔCt method. All experimental samples were in triplicate and PCR was repeated at least three times.
[0040] 1.6 Immunostaining
[0041] Mice were perfused sequentially with PBS and 4% paraformaldehyde (prepared in 0.1M phosphate buffer, pH 7.4) via the ascending aorta. After perfusion, the brain was removed, fixed, and then embedded in paraffin. For immunofluorescence staining, paraffin-embedded sections were cleared with xylene, dehydrated with graded ethanol, and rinsed thoroughly with PBS. After antigen retrieval in sodium citrate buffer, the sections were blocked with blocking buffer (1% BSA, 0.3% Triton X-100, and 10% goat serum in PBS) for 1 hour, and then incubated with the corresponding primary antibody (as described above) at 4°C overnight, and then incubated with fluorescent secondary antibodies labeled with Alexa Fluor-488 or Alexa Fluor-594 (Invitrogen) for 1 hour at room temperature.
[0042] For immunostaining of Ift172 and PSD-95, the previously reported tyramide signal amplification system (AFIHC023, Aifang Bio) was used. All images were taken using an upright microscope (BX51TF, Olympus, Japan) or a Nikon A1RHD25 confocal microscope system (Nikon, Japan).
[0043] 1.7 Hematoxylin and eosin staining
[0044] The eyeballs of each mouse were immediately immersed in 4% formaldehyde after enucleation. Then, they were dehydrated with graded ethanol, transparentized with xylene, and embedded in paraffin. Then, 5 μm thick sections were made, stained with standard hematoxylin and eosin (H&E) staining protocol, and observed under a microscope (BX51TF, Olympus, Japan).
[0045] 1.8 In situ hybridization
[0046] For in situ hybridization, adult brains of Ift172+ / - and littermate control mice were fixed in 4% PFA overnight and then cryoprotected in 30% sucrose for 2 days. Then cut into 20 μm thick sections, mounted on slides coated with poly-L-lysine, and dried at 55°C for 2 hours. After synthesizing digoxigenin-labeled RNA probes, hybridization was performed according to our previous method (Lang et al., Sci Rep. 2016; 6: 31126.). The following RNA probes were used to detect their expression in the hippocampus and cerebral cortex. The probe sequences are as follows:
[0047]
[0048] The nucleic acid probe was labeled with digoxigenin RNA after transcription (SP6 / T7; Roche Diagnostics Ltd., UK). The hybridization process was as previously reported (Lang et al., Sci Rep. 2016; 6: 31126.), and the signal was presented using 5-bromo-4-chloro-3-indolyl phosphate (Boehringer Mannheim) and 4-nitro blue tetrazolium salt (BioRad) as alkaline phosphatase substrates.
[0049] 1.9 Luciferase reporter assay
[0050] HEK293T cells were co-transfected with Gli3 plasmid (Addgene, #51246) and BDNF exon I, exon II, or exon IV luciferase reporter plasmids. 24 hours after transfection, cells were collected and used The luciferase assay system (Promega, #E2520) was used for analysis. For specific operation steps, please refer to the instruction manual.
[0051] 1.10ChIP-PCR detection
[0052] Chromatin immunoprecipitation experiments were performed according to the protocol provided by the SimpleChIP Enzyme Chromatin IP Kit (Cell Signaling Technology, #9003). Briefly, SH-SY5Y cells were transfected with Gli3 plasmid or treated with retinoic acid (MCE, #HY-14649) for 24 hours, and then fixed with 1% formaldehyde for 10 minutes to crosslink proteins with DNA. Cell nuclei were prepared and treated with Micrococcal nuclease for 20 minutes at 37°C to digest chromatin into 150-900 bp DNA / protein fragments. Gli3 rabbit mAb and ChIP grade protein G magnetic beads were used to immunoprecipitate DNA fragments bound to Gli3. Normal rabbit IgG and histone H3 antibodies were used as negative and positive controls for GAPDH, respectively. After chromatin was eluted from the beads, NaCl and proteinase K were added and incubated at 65°C for 2 hours to break crosslinks. After DNA was purified by adsorption column, standard PCR was performed using primers that recognize BDNF promoter I (177 bp). The primer sequences are as follows
[0053] Forward GATGCGCTCTTCGATTCACG (SEQ ID NO: 9)
[0054] Reverse TCACTGTGACTCCCTTGGT (SEQ ID NO: 10)
[0055] 1.11 Electron Microscope Studies
[0056] The method for measuring synaptic density by electron microscopy is described in a previous publication (Luo, et al., Int J Biol Macromol 213, 404-415 (2022)). 3 Anterior cingulate cortex (ACC) tissue was fixed in cold 1% OsO4 for 2 h, then dehydrated and embedded according to standard procedures. Ultrathin sections (60-80 nm) were stained with 2% uranyl acetate and lead acetate for 10 min in the dark. After washing and drying, copper grids were observed under a JEOL 200CX electron microscope at 100 kV. Synapses were identified by the presence of synaptic vesicles and postsynaptic density. Four mice were examined in each group.
[0057] 1.12 Stereotaxic Surgery
[0058] Stereotaxic injections were performed as previously reported. Briefly, mice were anesthetized with 2% isoflurane and placed in a stereotaxic apparatus (ZS Dechuang, China). A small incision was made to expose the skull and a small hole was drilled. Virus injections were performed using a glass pipette tightly connected to a microliter syringe (1 μl model, ZS Dechuang, China) via a glass needle and mounted on a syringe pump controlled by a microcontroller (ZS Dechuang, China). To sparsely label projection neurons in the CA1 region, the inventors used AAV2 / 9-hSyn-FLP (titer: 4.21 × 10 12 μg / mL) and AAV-nEF1a-fDIO-EGFP (titer: 5.12×10 12 μg / mL) virus (purchased from BrainVTA Co., Ltd., Wuhan). 1 microliter of AAV2 / 9-hSyn-FLP was diluted in sterile PBS in a 100-fold dilution gradient, with a final dilution of 1:10000. Then 100nl of diluted AAV2 / 9-hSyn-FLP was thoroughly mixed with an equal volume of AAV-nEF1a-fDIO-EGFP and injected bilaterally into the brain stereotaxically at a rate of 20nl / min (coordinates: AP-2.2mm, ML±1.7mm, DV-1.3mm). After the injection, the glass pipette stayed at the injection site for 5 minutes and then slowly moved out (over 2 minutes). The mice were placed on a heating pad until they began to wake up from the surgery.
[0059] 1.13 Patch clamp recording
[0060] Mice were anesthetized with 1% sodium pentobarbital and decapitated. The brain was quickly dissected, removed and placed in 4°C artificial cerebrospinal fluid (124mM NaCl, 3.0mM KCl, 2.0mM CaCl2, 1.2mM MgCl2-6H2O, 1.25mM Na2HPO4, 26mM NaHCO3 and 10mM glucose, pH=7.4), which was continuously filled with 95% O2 / 5% CO2. Coronal sections with a thickness of 300μm were made using a vibrating microtome (Leica, Germany). The sections were placed in a special clamp chamber with artificial cerebrospinal fluid, incubated at 32°C for 15 minutes, and then kept in the same clamp chamber at room temperature for at least 60 minutes before recording.
[0061] For recording spontaneous inhibitory postsynaptic currents (sIPSCs), cells were held at 0 mV in the presence of NBQX (5 μM) and DAPV (50 μM) in voltage clamp mode. Electrodes (4-6 MΩ) were injected with an electrode solution containing the following reagents (mM): potassium D-gluconate 140, sodium chloride 0.2, HEPES 10, EGTA 1, MgATP 2 (pH 7.3, 290 mOsm). sIPSCs signals were acquired with a patch clamp amplifier (Axopatch 252200A, Molecular Devices, Union City, CA, USA) and analyzed using Clampfit 10.2 (Axon Instruments, Union City, CA, USA). sIPSCs were considered positive if the peak amplitude of the maximum (peak) change in negative current relative to the baseline noise was greater than 3 SD of the root mean square (RMS) of the noise. An average of 2 cells were recorded per slice, and 2-3 slices were recorded per mouse.
[0062] 1.14 In vivo electrophysiological recordings
[0063] Mice (4–5 months old, 8 per group) were anesthetized with isoflurane, mounted on a stereotaxic apparatus, and the skull was exposed. A unilateral hole was drilled above the dorsal region of the hippocampus until the intact dura mater was visible. After removing a small piece of dura mater, multichannel microelectrodes were implanted targeting the CA1 pyramidal cell layer at the following coordinates: AP: −2.2 mm; ML: 1.3–1.5 mm; DV: −1.0 mm. The electrodes consisted of 16 individually insulated tungsten wires (35 μm inner diameter, 300–900 Kohm impedance; Stablohm 675, California FineWire) arranged in an 8 × 8 pattern (tilted 15°–30°, ~150 μm spacing). Additional holes were drilled in the skull and two screws were implanted to reinforce the microelectrodes. The exposed space in the skull was then filled with medical brain glue (Worldprecision instruments, Florida, USA), and the entire electrode system was fixed with dental cement. The mice were returned to their original cages for at least one week of recovery before recording.
[0064] Before the formal experiment, mice were adapted to the recording room for 2 days. The movement trajectory was recorded continuously for 2 hours in the home cage, and the video tracking software (Tracking Master V3.0, Shanghai Vanbi Intelligent Technology Co., Ltd.) was used to record and analyze the movement trajectory. A multi-channel data acquisition system (Zeus, Bio-Signal Technologies, China) was used to record neural signals (0.3Hz-7.5kHz) from the implanted 16-channel array. The detection of sharp wave ripples (SWR) was limited to the "immobility period" of mice, that is, the speed was less than 0.5 cm / s. The local field potential LFP of all electrodes in the static period was bandpass filtered at 120-180Hz. The occurrence and characteristics of SWR were certified according to previous reports, that is, when more than one event was detected in a time window of 200 milliseconds, it was a SWR burst. If two or three events occurred, they were classified as double ripples and triple ripples.
[0065] 1.15 Anxious Behavior
[0066] Before testing, mice were allowed to adapt to the experimental room for 1 hour. 2 The open field test was performed in a box of 20 cm × 10 cm, and the mice were allowed to explore freely for 5 min, and the movement trajectory was tracked. The parameters measured included the total distance moved, the time spent in the central area, and the distance moved (EthoVision XT 287, Noldus). In the elevated cross test, the cross consisted of two open arms (35 × 7 cm 2 ) and two closed arms (35×7×15cm 3 ) from the central platform (7×7cm 2) extended outward and at 90°, 60 cm above the ground. The mouse was placed in the center of the maze, facing the closed arm, and allowed to explore freely for 10 min. The time the mouse spent in the total area and the open arm was recorded. The buried bead test was performed in a clean cage (30×18×15 cm 3 ) was conducted in a cage filled with corncob bedding approximately 5 cm thick. The bedding was gently compacted to make the surface flat. 20 black glass marbles were arranged evenly spaced in a 4×5 grid. Each mouse stayed in the cage for 30 minutes. An independent person counted the number of marbles buried to a depth of two-thirds of the bedding. The activities of the mice were videotaped.
[0067] 1.16 Three-Box Social Experiment
[0068] The test apparatus consists of three chambers: a middle chamber (40×20 cm 2 ) and two side chambers (40×20cm 2 ), two wire cages were placed diagonally in the side chambers. During the adaptation process, the test mice were placed in the middle chamber and allowed to explore freely for 10 minutes to adapt to the environment. On the second day, an age- and sex-matched unfamiliar mouse was placed in the wire cage on one side, and the test mouse was placed in the middle chamber again for 10 minutes of exploration. On the third day, a second age- and sex-matched unfamiliar mouse was placed in the previously empty wire cage on the other diagonal side, and the test mouse was introduced into the middle chamber again for 10 minutes of exploration. The time the mice spent in each chamber and sniffing the wire cages was analyzed using the TopScanTop View behavioral analysis system.
[0069] 1.17 Fear conditioning experiment
[0070] Mice were placed in a fear conditioning apparatus (7” wide, 7” deep x 12” high, Coulbourn) with a metal grid floor and allowed to explore for 2 minutes. After the adaptation period, the mice were given a 29-second 85 dB tone stimulus followed by a 1-second 0.7 mA electric shock for a total of 6 times, with 30 seconds between each. On the second day, the mice were placed in the same test room as the first day of conditioning, but only the tone stimulus was given, and the number and duration of freezing of the mice were recorded using the TopScan Top View Behavior Analysis System.
[0071] 1.18 New Object Recognition Test
[0072] The mice were placed in an odorless plastic box (35×35×35 cm 3) with medium overhead lighting. On day 1, mice were allowed to freely explore two identical objects in the chamber for 15 min. On day 2, one of the objects was replaced with a new object of a different shape, placed in the same location, and the mice were allowed to explore as before for 15 min. The time the mice spent exploring each object was recorded and analyzed using the TopScan Top View Behavior Analysis System.
[0073] 1.19 Forced swim test
[0074] The mice were placed individually in a cylinder (25×13.5m 2 ) for 6 minutes, and the water temperature was maintained at 23±1°C. The instrument analysis software was used to calculate the immobility time, which was the total time (240 seconds) minus the activity time. After the test, the mice were wiped dry and returned to their original cages.
[0075] 1.20 Grooming behavior
[0076] The recording method of grooming behavior was as previously reported. In brief, the grooming behavior of mice, including face rubbing, scratching / rubbing the head and ears, and body grooming, was recorded between 19:00 and 21:00 every day. After the recording, the phenotype was analyzed by video recording by personnel independent of the experiment.
[0077] 1.21 Statistics
[0078] Statistical analysis was performed using Prism 9.0 (GraphPad). All data are presented as mean ± SD of three or more independent experiments. Histological data were analyzed using Student's t-test (two-group comparison) or one-way ANOVA with Tukey's multiple comparison test. The significance thresholds for all experiments were *p < 0.05, **p < 0.01, and ***p < 0.001.
[0079] Example 2 Experimental results
[0080] 2.1 Ift172+ / - mice exhibit abnormal behavioral phenotypes
[0081] Ift172 is the largest Ift family member, and most of its domains are thought to be involved in intraflagellar transport. To analyze the possible role of Ift172 in cognitive impairment in patients with BBS (Bardet-Biedl syndrome), CRISPR / Cas9-mediated genome editing was used to selectively target exons 2 to 8 of Ift172 to eliminate the major isoform of Ift172, and haploinsufficient mice (Ift172+ / -) ( Figure 1A). As expected, Ift172+ / - mice were viable, fertile, and had a 50% reduction in Ift172 protein expression and mRNA transcript levels in the testis, where Ift172 is most abundantly expressed ( Figure 1 B and C). Impressively, Ift172+ / - mice displayed pronounced stereotyped grooming. Analysis showed that grooming time was doubled compared to wild-type controls ( Figure 1 D). Then, a series of behavioral tests were performed to reveal the abnormal phenotype caused by Ift172 haploinsufficiency. In the open field test, Ift172+ / - mice showed stronger activity tendencies at the edge compared with controls at similar activity levels ( Figure 1 EG). In addition, the inventors used a modified version of the three-box social test to explore the mice's spontaneous social interaction preferences and their ability to discriminate social novelty. On the first day of the test, Ift172+ / - and control mice had no position preference between the center area and the two side boxes ( Figure 1 H). However, on the next two days of testing, Ift172+ / - mice showed strong impairments in social interaction, as measured by the time spent approaching and sniffing the stranger mouse. Notably, on the second day of testing, Ift172+ / - mice showed no significant preference for the companion (stranger 1) compared to the empty cage on the opposite side (empty, Figure 1 K), and even when a second social partner (Stranger Mouse II) was introduced into the previously empty cage on the third day of the test, they tended to prefer the old partner (Stranger Mouse 1), while WT mice showed normal social interaction behaviors (Figures I, J, K).
[0082] To assess anxiety-like behavior, elevated maze and bead-burying tests were performed. Results showed that although the time spent exploring the open arms of Ift172+ / - mice was not significantly different from that of WT mice, the number of beads buried was more than doubled ( Figure 1 L), indicating the presence of mild anxiety-like behavior. In the novel object task and fear conditioning test, Ift172+ / - mice did not show increased exploration time for novel objects and decreased freezing time ( Figure 1 M and N). However, in the forced swimming test, no abnormalities were found in Ift172+ / - mice. To exclude that the abnormal behavior of Ift172+ / - mice was due to retinal degeneration with visual impairment, retinal H&E staining was performed, which demonstrated the absence of pathological changes. At the same time, by in situ hybridization or fluorescent staining of specific sublayer biomarkers, it was found that Ift172+ / - mice showed broadly normal cortical or hippocampal development. In summary, Ift172+ / - mice exhibited repetitive grooming, mild anxiety-like behavior, and excessive and spontaneous memory impairment, especially abnormal social interactions and defects in discerning social novelty.
[0083] 2.2 Gene enrichment analysis of brain tissue of IFT172+ / - mice
[0084] To further identify the underlying mechanisms of abnormal behavioral responses in Ift172+ / - mice, RNA sequencing (RNA-seq) was performed to determine the global transcriptional profile of hippocampi isolated from WT and Ift172+ / - mice. A total of 939 differentially expressed genes (DEGs) were found in Ift172+ / -, of which 516 DGEs were upregulated and 423 DEGs were downregulated ( Figure 2 A and B). Gene Ontology (GO) analysis showed that these DEGs were mainly involved in axonogenesis, axon development and synaptic plasticity ( Figure 2 C), indicating that neural circuit connectivity and synaptic function may be impaired. Interestingly, the expression of ASD-related postsynaptic proteins in the hippocampus of Ift172+ / - mice was significantly reduced compared with wild-type mice, which may explain the typical social interaction and novelty discrimination deficits of Ift172+ / - mice ( Figure 2 D). Taken together, the RNA-seq data suggest that Ift172 haploinsufficiency may impair synaptic function in the brain.
[0085] 2.3Ift172 haploinsufficiency reduces BDNF production and dendritic spine density in pyramidal neurons
[0086] The development and function of synapses are highly dependent on the expression of brain-derived neurotrophic factor (BDNF), and the loss of BDNF is closely associated with many neuropsychiatric diseases. To determine how Ift172 affects the BDNF signaling pathway, mouse cortical and hippocampal tissue proteins were extracted, and semi-quantitative immunoblot analysis of BDNF and molecules in its downstream signaling pathways was performed. Reduced levels of BDNF, p-TrkB (activated BDNF receptor), p-Erk1 / 2, and PSD-95 were observed in Ift172+ / - brain samples ( Figure 3 A and B). Immunohistochemical staining in sagittal section ( Figure 3 C) and immunofluorescence staining of the cortex and hippocampus further confirmed that BDNF decreased in the brain of Ift172+ / - mice ( Figure 3DE). Considering that BDNF plays a key role in the development and maturation of dendritic spines, we investigated whether Ift172 haploinsufficiency would induce structural changes in pyramidal neurons. First, the dendritic spine density of CA1 pyramidal neurons specifically labeled with adeno-associated virus 2 / 9-hSyn-FLP and rAAV-nEF1a-rAAV-fDIO-EGFP (enhanced green fluorescent protein) was detected in WT and Ift172+ / - mice using a sparse labeling technique. The results showed that the dendritic spine density of pyramidal cells in Ift172+ / - mice was significantly lower than that in WT mice ( Figure 3 FH). Since a dendritic spine can house multiple synapses, the number of synapses in 24 defined CA1 regions was subsequently quantified by electron microscopy (EM). As expected, the level of synaptic density was significantly reduced in Ift172+ / - mice ( Figure 3 IJ). At the same time, anti-Arl13b staining confirmed that the number of primary cilia in Ift172+ / - mice was reduced. In summary, Ift172 haploinsufficiency may lead to reduced dendritic spines in pyramidal neurons and dysfunctional BDNF signaling and structural defects.
[0087] 2.4Ift172+ / - mice exhibit abnormal inhibitory synaptic transmission, theta oscillations, and sharp wave ripples in the CA1 region
[0088] Inhibitory neuron dysfunction has been consistently reported in patients with autism spectrum disorder (ASD) as well as in genetic mice in many ASD models. Interestingly, disrupted primary ciliary signaling caused by BBS protein deficiency or mutant ciliotaxin alleles in humans may also lead to abnormal interneuron morphogenesis and synaptic connectivity. Based on this observation, the inventors performed immunofluorescence staining of parvalbumin interneurons. The total density of PV+ interneurons in the CA1 region of the hippocampus of Ift172+ / - mice was significantly reduced compared with wild-type littermates (n=5 for each genotype, p<0.01; Figure 5—figure supplement 1A). Figure 4 A and B). We then measured spontaneous inhibitory postsynaptic currents (sIPSCs) in CA1 pyramidal neurons in freshly prepared brain slices and found that both the amplitude and frequency of sIPSCs were significantly reduced in Ift172+ / - mice ( Figure 4 CE). These data further support the fact that inhibitory synaptic transmission in the CA1 region is significantly impaired.
[0089] Mixed neural oscillations of different frequency bands in the hippocampus are associated with emotional valence and memory performance. Theta cycle is the most prominent oscillatory activity in the CA1 region and is closely related to many stress-induced psychiatric disorders. The inventors then performed local field potential recordings in the CA1 region to study the neural oscillations and SWR emission during rest in mice that moved freely in their home cages ( Figure 4F and G). Ift172+ / - mice had a higher incidence of SWRs compared to their wild-type littermates ( Figure 4 H), but the duration and release pattern are normal ( Figure 4 I)( Figure 4 J). The inventors also analyzed the relative power differences of neural oscillations in different frequency bands and found that the theta oscillation power of Ift172+ / - mice was enhanced ( Figure 4 K). Because theta range oscillations are closely associated with emotional behaviors and are vulnerable to stress, our data suggest that altered ensembles of neural activity may underlie the anxiety-like behaviors and abnormal cognition exhibited by Ift172+ / - mice.
[0090] 2.5 Administration of 7,8-DHF rescued behavioral changes in Ift172+ / - mice
[0091] 7,8-Dihydroxyflavone (7,8-DHF), a well-established BDNF mimetic compound, is a potent small molecule TrkB agonist that shows significant therapeutic effects on a variety of BDNF-related human diseases. To further explore whether BDNF deficiency is associated with abnormal behavior in Ift172+ / - mice, 26 Ift172+ / - mice were injected with 7,8-DHF or vehicle at 2 months of age. The behavioral phenotypes of the animals were reassessed 2 months after drug treatment. As expected, Ift172+ / - mice treated with 7,8-DHF exhibited greater activity in the open field test, as evidenced by a greater distance traveled in the entire chamber or just in the middle area ( Figure 5 AC). In addition, social preference and social interaction were also improved in Ift172+ / - mice after administration of 7,8-DHF ( Figure 5 DG). At the same time, new objective recognition and fear conditioning tests also supported that the memory impairment of Ift172+ / - mice was significantly reduced after 7,8-DHF treatment ( Figure 5 H and I). However, in the bead burying test, 7,8-DHF did not change the number of beads buried in Ift172+ / - mice ( Figure 5 J).
[0092] 2.6Ift172 regulates BDNF expression through transcription factor Gli3
[0093] Many IFT proteins are involved in the activation of the Hh pathway by Gli transcription factors. Interestingly, in the absence of IFT172, cells can neither promote the formation of Gli3 activator (Gli3A) nor regulate the production of Gli3 repressor (Gli3R), and cannot respond to the effects of Hh ligands or upstream signals. This fact prompted the inventors to study whether Gli3 is an intermediate molecule that mediates BDNF deficiency caused by haploinsufficiency of IFT172. SH-SY5Y cells were then transfected with IFT172-specific siRNA and control (SantaCruz, #sc-94558), followed by immunoblot analysis to confirm the expression of Gli3. Notably, silencing of IFT172 reduced the expression of both Gli3A and Gli3R, as well as the expression of BDNF at the transcriptional and translational levels ( Figure 6 A and B). To further reveal the regulatory role of Gli3, SH-SY5Y cells were transfected with siGli3 (Santa Cruz, #sc-35483) or Gli3-GFP plasmid to achieve knockdown or overexpression of Gli3. Interestingly, the expression of BDNF also showed concomitant downregulation or upregulation ( Figure 6 CF). These results strongly suggest that Gli3 is likely to be an upstream transcription factor of BDNF. Gli2 is another candidate transcription factor downstream of the IFT protein complex. To rule out this possibility, similar loss / gain of function experiments were performed on Gli2, and it was found that the expression of BDNF was not related to the expression level of Gli2, indicating that Gli2 may not be involved in the regulation of the activity of the BDNF-TrkB signaling pathway.
[0094] To further confirm that Gli3 exerts its regulatory effect by directly binding to the promoter region of Bdnf, luciferase assays were performed using plasmids of different Bdnf promoters bound to luciferase. Figure 6 As shown in G, DNA sequence analysis found a potential Gli3 binding site in the exon I promoter region. Gli3 and promoter constructs were co-transfected into cultured HEK293 cells, and cell lysates were extracted for luciferase assay. The results confirmed that the exon I promoter is the main binding site for Gli3, because mutation of the internal motif completely abolished the promoter activity ( Figure 6 H). To further confirm that Gli3 acts as a transcription factor for BDNF, the inventors performed chromatin immunoprecipitation (ChIP) assays using Gli3-specific antibodies or control IgG after SH-SY5Y cells were transfected with Gli3 plasmids and treated with retinoic acid. PCR analysis showed that Gli3 interacted with the Bdnf exon I promoter. Therefore, these results indicate that Gli3, as a transcription factor for BDNF, is regulated by Ift172 in primary cilia.
[0095] The above results describe the basic principles, main features and advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the attached claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention. Any figure mark in the claims should not be regarded as limiting the claims involved.
[0096] In addition, it should be understood that although this specification is described in terms of implementation methods, not every implementation method contains only one independent technical solution. This description method of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment can also be appropriately combined to form other implementation methods that can be understood by those skilled in the art.
Claims
1. Application of IFT172 haploinsufficiency as a marker for the preparation of autism diagnostic reagents.
2. The use according to claim 1, characterized in that: The autism is autism spectrum disorder (ASD).
3. The use according to claim 1 or 2, characterized in that: The level of IFT172 haploinsufficiency was identified by a method selected from high-throughput sequencing, quantitative PCR and protein electrophoresis.
4. A method for autism research for non-disease diagnosis and treatment purposes, characterized in that: The method comprises detecting the level of IFT172 haploinsufficiency in the subject; using the IFT172 level value of a normal person as a control; and an IFT172 haploinsufficiency level lower than the control indicates a high risk of autism.
5. A system for autism diagnosis, comprising: 1) Reagents for detecting haploinsufficiency levels of IFT172 in subjects; 2) The device includes a data input module, a data comparison module and a conclusion output module.
6. The system according to claim 5, characterized in that The data input module is used to input the IFT172 haploinsufficiency level in the sample to be tested; the data comparison module is used to compare the IFT172 haploinsufficiency level in the sample to be tested with a control value; the control value is the IFT172 level of a normal person; the conclusion output module is used to output the conclusion according to the following standards: if the IFT172 haploinsufficiency level in the sample to be tested is lower than the control, it indicates a high risk of autism.
7. Use of reagents that eliminate or alleviate the defects caused by haploinsufficiency of IFT172 in the preparation of drugs for the treatment of autism.
8. The use according to claim 7, characterized in that: The agent is selected from an IFT172 overexpression agent, a BDNF overexpression agent, a BDNF mimetic compound and / or a TrkB agonist.
9. The use according to claim 8, characterized in that: The TrkB agonist is 7,8-DHF.
